anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A therapy useful for preventing tumor recurrence in patients with Ta, T1 and Tis transitional cell carcinoma is provided. The therapy is an adjuvant intravesical therapy, i.e., it is employed on patients following transurethral resection of the Ta, T1 or Tis carcinoma. The therapy comprises the steps of reducing the volume of urine in the bladder of the patient to a value of about 10 ml or less; and then administering an aqueous solution containing at least 2 mg/ml of MMC to the bladder of the patient for a period of at least about 120 minutes. The volume of solution administered to the bladder of the patient is at least about 20 ml. Preferably, the therapy is administered to the patient weekly multiple times. Preferably, the therapy further comprises the step of reducing the amount of urine produced by the patient during the time MMC is administered to the patient to a value of 1 ml/min or less. Preferably, the therapy further comprises the step of administering an alkalinizing agent to the patient before the MMC dosing solution is administered to the patient. The alkalinizing agent is administered in an amount sufficient to increase the pH of the urine produced by the patient during the time of MMC administration to a value of about 6.5 or greater. Preferably, the alkalinizing agent is administered orally.
There exists a bidirectional relationship between oral health and general well-being, with an imbalance in oral symbiotic flora posing a threat to overall human health. Disruptions in the commensal flora can lead to oral diseases, while systemic illnesses can also impact the oral cavity, resulting in the development of oral diseases and disorders. Porphyromonas gingivalis and Fusobacterium nucleatum, known as pathogenic bacteria associated with periodontitis, play a crucial role in linking periodontitis to accompanying systemic diseases. In periodontal tissues, these bacteria, along with their virulence factors, can excessively activate the host immune system through local diffusion, lymphatic circulation, and blood transmission. This immune response disruption contributes to an imbalance in osteoimmune mechanisms, alveolar bone resorption, and potential systemic inflammation. To restore local homeostasis, a deeper understanding of microbiota-host interactions and the immune network phenotype in local tissues is imperative. Defining the immune network phenotype in periodontal tissues offers a promising avenue for investigating the complex characteristics of oral plaque biofilms and exploring the potential relationship between periodontitis and associated systemic diseases. This review aims to provide an overview of the mechanisms underlying Porphyromonas gingivalis- and Fusobacterium nucleatum-induced alveolar bone resorption, as well as the immunophenotypes observed in host periodontal tissues during pathological conditions.
In this clinical trial 50 patients with insulin dependent type 2 diabetes will be randomised in two study arms: monitoring of blood glucose and blood pressure using a telemedical device or in an arm with treatment as usual. Patients will the following measurement devices: blood glucose, blood pressure. Both devices can communicate with a mobile phone, which will also be provided to the patients. The mobile phone will transfer the data to a central, safe server. Patients will receive automated reminder/feedback. Caregivers can evaluate the transferred data whenever necessary via a web-based access. Data will be presented in tables as well as trend figures.
BACKGROUND: Urinary incontinence is common in patients with genitourinary syndrome of menopause (GSM). A retrospective cohort study was conducted to analyse the clinical efficacy of carbon dioxide laser combined with pelvic floor functional exercise for GSM with urinary incontinence, aiming to provide evidence for its clinical treatment.
METHODS: Patients diagnosed with GSM and urinary incontinence and admitted to our hospital from January 2021 to December 2022 were included and allocated to a control group (pelvic floor function exercise) and combined group (carbon dioxide laser combined with pelvic floor function exercise). Confounding factors among the groups were balanced by the propensity score matching method. The clinical efficacy, GSM scale scores, urinary indicators, urinary incontinence quality of life scale (I-QOL) scores and the degree of urinary incontinence of the groups were compared.
RESULTS: A total of 192 patients were included in this study, and 36 cases were included in each group after the propensity scores were matched. No statistical difference in baseline data was found between the groups (p > 0.05). The combined group had higher total effective rate and I-QOL scores but lower GSM symptom scale scores than the control group. Urination during daytime and nighttime was less frequent in the combined group than in the control group, which showed a lower degree of urinary incontinence (p < 0.05).
CONCLUSIONS: Combining carbon dioxide laser treatment with pelvic floor exercises is potentially effective for patients with GSM and urinary incontinence. This combined approach not only alleviated GSM and urinary incontinence symptoms but also reduced the severity of urinary incontinence, promoted bladder function recovery and enhanced overall quality of life.
Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart. Peripheral blood and endomycardial biopsies will also be obtained for single cell RNAseq analyses.
The invention discloses a carrier adhesive for plasters and patches and a preparation method thereof. The adhesive is prepared from the following components: 100 parts by weight of a styrene-isoprene-styrene (SIS) block copolymer; 65-85 parts by weight of a plasticizer; 130-155 parts by weight of tackifying resin; and 0.1-0.5wt% of an antioxidant additionally. The styrene-isoprene-styrene (SIS) block copolymer has a linear structure, a block ratio of 14-16/86-84, and a molecular weight of 0.1-0.13 million. The diblock content is 18-25wt%, and the diblock molecular weight is 60-80 thousands. The carrier adhesive provided in the invention not only has good adhesion when a total drug carrying amount is not higher than 20% of the carrier adhesive, but also has a low peeling force, thus being in favor of generating small physical stimulations resulted from hair or skin pulling during peeling, and reducing the pain when peeling plasters or patches. At the same time, the drug adding temperature is low, and the applying temperature after drug adding is lower.
The intervention consist of 8 sessions in which participants learned three main different practices: body scan, sitting meditation, and yoga practice. Participants are instructed to regularly engage in home mindfulness practice of these new learned skills (45 minutes a day for 6 days a week). Home exercises include formal mindfulness practice (i.e., meditation and yoga) for about 30-35 minutes a day and informal practice focused on bringing mindful awareness to everyday activities for about 10-15 minutes a day. Mp3 audio of meditations proposed at each session are provided to guide personal practice.
PURPOSE: A composition containing diphlorethohydroxycarmalol extracted from Ishige okamurae is provided to prevent and treat liver injury caused by carbon tetrachloride. CONSTITUTION: A composition for preventing or treating liver injury contains DPHC(diphlorethohydroxycarmalol) of chemical formula 1 or pharmaceutical acceptable salts thereof as an active ingredient. The compound is derived from Ishige okamurae plants. The composition for preventing or treating liver injury contains Ishige okamurae plant extract as an active ingredient. The extract is prepared using water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, citric acid, diethyl ether, or cyclohexane. A functional food for preventing or treating liver injury contains DPHC or the extract containing the same as an active ingredient.
On the first day, Avastin injection was given, 3mg/kg of which was diluted to 100ml of 0.9% sodium chloride injection. After mixing evenly, it was infused intravenously for 90 minutes (±15 minutes).
FIELD: medicine, dermatology. SUBSTANCE: method involves carrying out the complex immunocorrection on the background of therapy including desensibilization, use of indifferent ointments and ultraviolet irradiation. Complex immunocorrection method involves disintoxicating therapy using enterosorbent, for example, activated carbon by descending schedule for two months, immunomodulation with T-activine by prolonged schedule for at least one-half of year, normalization of liver function with carsil, vascular therapy with cinnarizine, antioxidant therapy with "Levit" and polyvitamins in combination with trace elements by alternating month course schedule for year. Method provides to obtain clinical-immunological remission. EFFECT: accelerated time of treatment. 2 ex
Methods for screening compounds to treat an oncological disorder regulated through a tumor-inducing pathway are provided. The compounds are administered to non-human animal subjects having a disease model, so that the subjects display pathology symptoms that correspond to the oncological disorder in humans. The subjects carry a regulatable transgene expression, of which is associated with tumor formation, and further carry regulatable genes for suppression of tumor formation. The disease-pathology symptoms are induced using a site-specific recombination system to induce expression of the transgene associated with tumor formation and negatively regulate or eliminate the genes for suppression of the tumor formation. The methods further involve analyzing tumor formation in subjects administered the compound and comparing appearance and amount of tumors in the subjects administered the compound with control subjects not administered the compound. Also included are a vector for engineering a disease model and a kit for its use.
1516359 Pharmaceutical preparations NIPPON KAYAKU KK 23 Sept 1975 [24 Sept 1974] 38993/75 Heading A5B Pharmaceutical preparations for oral cavity administration e.g. buccal tablets, sublingual tablets and ointments, with superior adhesion to local sites, comprising 10 to 60% by weight of sodium polyacrylate, 90 to 10% by weight of a pharmaceutical carrier, and 50 to 0.05% by weight of a pharmacologically active agent may be prepared by mixing the above components and then compression-moulding or kneading the resulting mixture. The pharmacologically active agent may be a steroid hormone; protein such as antiinflammatory enzymes and callicrein; peptide such as insulin, gastrin, secretin, leupeptin, a nitrate ester such as nitroglycerin and erythrityl tetranitrate; isoproterenol; methacholine; antiinflammatory steroid; antibiotic bactericide such as leucomycin, bleomycin and neomycin; lysozyme; chlorpheniramine maleate; a mixture of the methanesulphonates of dihydroergocarnine and dihydroergocristine; dextranase or a local anaesthetic e.g. lidocaine. The pharmaceutical carrier may be an excipient e.g. microcrystalline cellulose, mannitol, lactose, sorbitol, anhydrous calcium phosphate, amylose or powdered sucrose; or an ointment base e.g. white petrolatum, polyethylene glycol, a compatible mixture of peanut oil or purified sesame oil with beeswax, or a compatible mixture of polyethylene and liquid paraffin.
The invention relates to molecules inhibiting biologically active compounds and further comprising moieties specifically cleavable by a reagent produced by a target cell. More specifically, the invention relates to inhibitors that bind, inhibit, suppress, neutralize, or decrease activity of a biologically active agent. Inhibitors comprise at least one moiety that bind, inhibit, suppress, neutralize, or decrease activity of a biologically active agent and at least one moiety that can be cleaved specifically by a reagent produced by target cells. The cleavage deactivates the inhibitor. Following cleavage, the active agent is liberated into the local environment. Administration of the inhibitor alone or together with the active agent suppress the compound's activity until it reaches the proximity of a target cell. This targeted specific release enables the agent concentration in a site to reach levels that have desired therapeutic effects without systemic toxicity. The invention also relates to production and uses of the inhibitors in diagnosis and treatment of a disease.
Approximately 200 patients with chronic low back pain lasting ≥12 weeks between the ages of 18-75 who applied to the outpatient clinic will be included in the study. Demographic data of the patients such as age, gender, body mass index and occupation will be recorded. The pain intensity of the patients will be evaluated with the Visual Analog Scale (VAS), their disability with the Oswestry disability index, their kinesiophobia with the Tampo scale for kinesiophobia (TSK), and their quality of life with the SF 36 quality of life scale. TSK is a 17-question scale developed to measure the fear of movement/re-injury. The scale has four answer options rated on a Likert scale (1=Strongly Disagree, 2=Disagree, 3=Agree, 4=Strongly Agree). The total score varies between 17 and 68. Oswestry disability index will be used to measure the person's level of functional disability in individuals with low back pain. Oswestry disability index includes ten subheadings: severity of pain, personal care, lifting loads, walking, sitting, standing, sleeping, sexual life, social life and travel. Each question is given a score between 0 (no disability) and 5 (full disability). The total score varies between 0 (no disability) and 50 (full disability). As the total score increases, functional status worsens. SF-36 short form index will be used to measure quality of life. SF 36 Short form is a questionnaire that provides wide-angle measurement within the quality of life scales and has a generic criterion feature. It consists of 36 questions in 8 categories under the headings of physical function, physical role difficulty, social function, mental health, vitality, pain, emotional role difficulty and general health. The answers to the questions are added as positive and negative and the total score varies between 0 and 100. A high score indicates good health.
NEW MATERIAL:A sulfamoylbenzoic acid derivative shown by the formula I (R1 is Cl, or phenoxy; R2 is H, halogen, lower alkyl, lower alkoxy, or methylenedioxy). EXAMPLE:4-Chloro-N-[4-(2-methoxyphenyl)-1-piperazinyl]-3-sulfamoylbenz amide. USE:A remedy for edema resulting from diseases of the heart, the kidney, or the liver. The remedy for cardiac incompetence and hypertension. A remedy for hyperuricacidemia, or gout. PREPARATION:A sulfamoylbenzoic acid shown by the formula II or its reactive derivative is reacted with a piperazine shown by the formula III by the use of a condensation agent to give a sulfamoylbenzoic acid derivative shown by the formul I.
Stroke is the abrupt loss of neurological function, due to disturbance of the blood flow in the brain. There is variety of crucial sign and symptoms that can occur during stroke include changes in the level of consciousness and impairments of sensation and motor or cognitive function loss. It also includes changes in perceptual and language functions. Worldwide, 55 million people died of stroke in 2002, and approximately 20 percent of these deaths occurred in South Asia. Predicting amounts of deaths from stroke will increase to 63 million in 2015 and 78 million by 2030 with the mass occurring in the poor countries of the world. Rehabilitation plays a major role in minimizing activity limitation and participation restriction or to decrease extent of impairments. Stroke can cause variety of impairments which have greater impact on the patient quality of life. Hemiparesis is the common impairment, in which involvement of upper limb is commonly seen.

mCIMT and BAT techniques both play an important role in the treatment of stroke. In this research, both techniques will be use to evaluate which treatment technique is better for upper extremity chronic stroke patients. Written informed consent will be taken. Each participant will be requested to draw either number one or number two from a box. Number one will be allocated to Group A and number two will be allocated to group B. The A group will receive mCIMT after applying conservative management and Group B will receive BAT for 5 days a week for 8 weeks.
According to the recommendations of the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) statement and the Russian guidelines for limb ischemia treatment (2010), reconstructive surgery is preferred for type D lesions. Patients with type C lesions can be managed by either stenting or bypass surgery. Despite the fact that aorta-femoral reconstructions long-term results are better than the diffuse aorta-iliac lesions endovascular treatment results, the surgery risk is significantly higher than the endovascular surgery risk regarding criteria of mortality, complications, and return to normal activity.

All reports of iliac arteries stenosis percutaneous angioplasty indicate that the primary technical and clinical success rate exceeds 90%. The figure reaches 100% in the case of local lesions. The technical success of iliac arteries long occlusions recanalization reaches 80-85%. Improvement of endovascular equipment designed for the total occlusions treatment increases technical success of recanalization. The TASC II materials summarize the several large studies results which present the data on the operated segment artery patency at the level of 70-81% within 5-8 years of follow up. A large number of authors note the actuality of aortic-iliac type C and D segment lesions endovascular treatment recommendations revision according to the TASC II.
BACKGROUND: Non-invasive brain stimulation is considered as a promising technology for treating patients with disorders of consciousness (DOC). Various approaches and protocols have been proposed; however, few of them have shown potential effects on patients with vegetative state (VS). This study aimed to explore the neuro-modulation effects of intermittent theta burst stimulation (iTBS) on the brains of patients with VS and to provide a pilot investigation into its possible role in treating such patients.
METHODS: We conducted a sham-controlled crossover study, a real and a sham session of iTBS were delivered over the left dorsolateral prefrontal cortex of such patients. A measurement of an electroencephalography (EEG) and a behavioral assessment of the Coma Recovery Scale-Revised (CRS-R) were applied to evaluate the modulation effects of iTBS before and after stimulation.
RESULTS: No meaningful changes of CRS-R were found. The iTBS altered the spectrum, complexity and functional connectivity of the patients. The real stimulation induced a trend of decreasing of delta power at T1 and T2 in the frontal region, significant increasing of permutation entropy at the T2 in the left frontal region. In addition, brain functional connectivity, particularly inter-hemispheric connectivity, was strengthened between the electrodes of the frontal region. The sham stimulation, however, did not induce any significant changes of the brain activity.
CONCLUSIONS: One session of iTBS significantly altered the oscillation power, complexity and functional connectivity of brain activity of VS patients. It may be a valuable tool on modulating the brain activities of patients with VS.
One aspect of the subject matter described in this disclosure can be implemented in a device capable of use in estimating blood pressure. The device includes one or more arterial sensors configured to obtain arterial measurements at two or more elevations. The device additionally includes one or more processors configured to determine one or more calibration parameters for a first blood pressure model based on the arterial measurements and a hydrostatic pressure difference between at least two of the elevations. The processors also are configured to determine a first blood pressure based on the first blood pressure model, the calibration parameters and the arterial measurements. The processors also are configured to determine a second blood pressure based in part on a second blood pressure model, one or more calibration parameters and the arterial measurements. The processors are further configured to provide a final blood pressure based on the first and second blood pressures.
PURPOSE: Acute kidney injury (AKI) is a common complication of acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and inflammation is the potential link between AKI and AECOPD. However, little is known about the incidence and risk stratification of AKI in critically ill AECOPD patients. In this study, we aimed to establish risk model based on white blood cell (WBC)-related indicators to predict AKI in critically ill AECOPD patients.
MATERIAL AND METHODS: For the training cohort, data were taken from the Medical Information Mart for eICU Collaborative Research Database (eICU-CRD) database, and for the validation cohort, data were taken from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database. The study employed logistic regression analysis to identify the major predictors of WBC-related biomarkers on AKI prediction. Subsequently, a risk model was developed by multivariate logistic regression, utilizing the identified significant indicators.
RESULTS: Finally, 3551 patients were enrolled in training cohort, 926 patients were enrolled in validation cohort. AKI occurred in 1206 (33.4%) patients in training cohort and 521 (56.3%) patients in validation cohort. According to the multivariate logistic regression analysis, four WBC-related indicators were finally included in the novel risk model, and the risk model had a relatively good accuracy for AKI in the training set (C-index, 0.764, 95% CI 0.749-0.780) as well as in the validation set (C-index, 0.738, 95% CI: 0.706-0.770). Even after accounting for other models, the critically ill AECOPD patients in the high-risk group (risk score > 3.44) still showed an increased risk of AKI (odds ratio: 4.74, 95% CI: 4.07-5.54) compared to those in low-risk group (risk score ≤ 3.44). Moreover, the risk model showed outstanding calibration capability as well as therapeutic usefulness in both groups for AKI and ICU mortality and in-hospital mortality of critical ill AECOPD patients.
CONCLUSION: The novel risk model showed good AKI prediction performance. This risk model has certain reference value for the risk stratification of AECOPD complicated with AKI in clinically.
PROBLEM TO BE SOLVED: To obtain the subject new compound useful as a perfume raw material excellent in heat resistance and capable of remaining, even when added to foods passing through heating processes, such as confectioneries, e.g. cookies, processed oils and fats, or breads, and subsequently baked. SOLUTION: A compound of formula I [either one of R groups is a group of formula II (n is 1-4), and the other two groups are H]. For example, glycerol mono-6-hydroxydodecanoic acid ester. The compound of formula I is obtained by esterifying a 6-hydroxyalkanoic acid with glycerol or subjecting an ε-alkyl-ε- lactone and glycerol to a transesterification reaction. This compound is preferably used in an amount of 0.1-50wt.% based on a perfume composition in order to effectively generate an aroma.
Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits. At the 30-day evaluation, patients in the placebo group will cross over to the treatment group for the remainder of the study and all patients will be given a 60-day supply of treatment capsules covering the 90-day follow-up visit.